Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Entecavir

Nature Reviews Drug Discovery volume 4, pages 535–536 (2005)Cite this article

Abstract

In March 2005, entecavir (Baraclude; Bristol-Myers Squibb) was approved by the US FDA for the treatment of hepatitis B virus (HBV) infection. It is the most potent inhibitor of the HBV DNA polymerase to be approved so far.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Lee, W. M. Hepatitis B virus infection N. Engl. J. Med. 337, 1733–1745 (1997).

    Article  CAS  Google Scholar 

  2. Malik, A. H. & Lee, W. M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. 132, 723–731 (2000).

    Article  CAS  Google Scholar 

  3. Keeffe, E. B. et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. 2, 87–106 (2004).

    Article  CAS  Google Scholar 

  4. Fung, S. K. & Lok, A. S. Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin. Gastroenterol. Hepatol. 2, 839–848 (2004).

    Article  CAS  Google Scholar 

  5. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021797,021798lbl.pdf> (2005).

  6. Innaimo, S. F. et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41, 1444–1448 (1997).

    Article  CAS  Google Scholar 

  7. Genovesi, E. V. et al. Efficacy of the carbocyclic 2′-deoxyguanosine analogue BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42, 3209–3217 (1998).

    Article  CAS  Google Scholar 

  8. Marion, P. L. et al. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. 46, 82–88 (2002).

    Article  CAS  Google Scholar 

  9. Levine, S. et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46, 2525–2532 (2002).

    Article  CAS  Google Scholar 

  10. Zoulim, F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. 64, 1–15 (2004).

    Article  CAS  Google Scholar 

  11. Locarnini, S. Molecular virology of hepatitis B virus. Semin. Liver Dis. 24 S1, 3–10 (2004).

    Article  CAS  Google Scholar 

  12. Lok, A. S. & McMahon, B. J. Chronic hepatitis B: update of recommendations. Hepatology 39, 857–861 (2004).

    Article  Google Scholar 

  13. Hadziyannis, S. et al. Adefovir dipivoxil demonstrates sustained efficacy in HBEAG-chronic hepatits B patients. J. Hepatol. 42, A492 (2005).

    Article  Google Scholar 

  14. Bartholomeusz, A. et al. Characterisation of hepatitis B virus adefovir resistance mutations outside the polymerase active site background/aims: resistance to ADV was originally found in the D domain of the HBV polymerase at rtN236T. Antiviral Res. 65, A32 (2005).

    Google Scholar 

  15. Maynard, M. et al. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J. Hepatol. 42, 279–281 (2005).

    Article  CAS  Google Scholar 

  16. Fung, S. K. & Lok, A. S. Management of hepatitis B patients with antiviral resistance. Antivir. Ther. 9, 1013–1026 (2004).

    CAS  PubMed  Google Scholar 

  17. Colonno, R. J. et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology 40, 661A (2004).

    Google Scholar 

  18. Tenney, D. J. et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 40, 245A (2004).

    Google Scholar 

  19. Gish, R. G. et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection. A two-year study. J. Hepatol. 2005 Apr 11 [Epub ahead of print].

  20. Dore, G. J. et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. 189, 1185–1192 (2004).

    Article  CAS  Google Scholar 

  21. van Bommel, F. et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40, 1421–1425 (2004).

    Article  Google Scholar 

  22. Pozniak, A. Emtricitabine/tenofovir disoproxil fumarate. Drugs 64, 2083–2084 (2004).

    Article  Google Scholar 

  23. Janssen, H. L. et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365, 123–129 (2005).

    Article  CAS  Google Scholar 

  24. FDA labeling information [online], <http://www.fda.gov/cder/foi/label/2005/103964s5037lbl.pdf> (2005).

  25. Zoulim, F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lessons from experimental models. J. Antimicrob. Chemother. 55, 608–611 (2005).

    Article  CAS  Google Scholar 

  26. Soriano, V. et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19, 221–240 (2005).

    Article  Google Scholar 

  27. Han, S. H. et al. Results of a one-year international phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis. J. Hepatol. 40, 16 (2004).

    Article  Google Scholar 

  28. Shiffman, M. L. et al. A double-blind, placebo-controlled trial of emtricitabine (FTC, emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection. Hepatology 40, 172A (2004).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mulago Hospital/Makerere University,PO BOX 7051, Kampala, Uganda

    Christopher K. Opio

  2. University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, 75390-9151, Texas, USA

    William M. Lee

  3. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Christopher K. Opio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William M. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to William M. Lee or Peter Kirkpatrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opio, C., Lee, W. & Kirkpatrick, P. Entecavir. Nat Rev Drug Discov 4, 535–536 (2005). https://doi.org/10.1038/nrd1780

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1780

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing